Orthopaedic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Clin Orthop Relat Res. 2014 Oct;472(10):3179-87. doi: 10.1007/s11999-014-3734-3. Epub 2014 Jun 26.
Small case series suggest that preoperative transcatheter arterial embolization minimizes bleeding and facilitates surgery for hypervascular metastatic bone tumors. However, control groups would make our confidence in clinical recommendations stronger, but small patient numbers make prospective trials difficult to conduct on this topic.
QUESTIONS/PURPOSES: In this case-control study, we asked whether (1) patients who undergo embolization have less estimated blood loss and/or shorter operative time than patients who do not have embolization; (2) larger tumor size, greater initial tumor vascularity, and longer interval from embolization to surgery are associated with greater estimated blood loss and packed red blood cell transfusion volume; and (3) embolization does not affect renal function in patients with normal preoperative renal function.
We retrospectively reviewed records of patients with hypervascular bone metastases treated at our institution between 1998 and 2008. Twenty-seven patients with renal cell carcinoma and 12 with thyroid carcinoma who underwent embolization before 41 surgical procedures were matched to 41 patients who did not have embolization with respect to age, diagnosis, tumor size and potential vascularity, and procedure type; matching was performed without knowledge of outcomes. In univariate and multivariate analyses, age, tumor size, use of embolization, surgery type and risk, embolization-to-surgery interval, and degree of devascularization were evaluated for correlations with estimated blood loss, packed red blood cell transfusion volume, operative time, and postembolization renal function.
Overall, patients who had embolization had less mean estimated blood loss (0.90 versus 1.77 L; p = 0.002), packed red blood cell transfusion volume (2.15 versus 3.56 U; p = 0.020), and operative time (3.13 versus 3.91 hours; p < 0.001). Larger tumor size correlated with greater estimated blood loss (r = 0.451; p = 0.003), packed red blood cell transfusion volume (r = 0.50; p = 0.002), and operative time (r = 0.595; p < 0.001). Neither the interval for embolization to surgery nor the degree of devascularization correlated with estimated blood loss or transfusion volume. In open rodding with intralesional curettage, transcatheter arterial embolization was associated with reduced estimated blood loss, transfusion volume, and operative time. Packed red blood cell transfusion volume was not reduced by embolization in intramedullary nailing procedures with the patient numbers available. Among patients with normal preoperative renal function who had embolization, creatinine levels remained normal. Mild transient, reversible renal function change occurred in one patient with preoperatively abnormal renal function.
This study suggests that preoperative embolization probably reduces estimated blood loss, particularly for large tumors and during open femoral procedures.
小病例系列研究表明,术前经导管动脉栓塞术可减少出血并有利于治疗富血管转移性骨肿瘤。然而,对照组将使我们对临床推荐的信心更强,但小患者数量使得前瞻性试验难以针对该主题进行。
问题/目的:在本病例对照研究中,我们想知道(1)接受栓塞治疗的患者与未接受栓塞治疗的患者相比,失血量估计值和/或手术时间是否更少;(2)肿瘤较大、初始肿瘤血管生成较多以及栓塞与手术之间的时间间隔较长是否与失血量估计值和红细胞输注量较大相关;(3)栓塞是否会影响术前肾功能正常的患者的肾功能。
我们回顾性分析了 1998 年至 2008 年期间在我院接受治疗的患有富血管性骨转移的患者的记录。对 27 例患有肾细胞癌和 12 例患有甲状腺癌的患者进行了栓塞治疗,这些患者在 41 例手术前进行了栓塞治疗,然后与 41 例未进行栓塞治疗的患者进行了年龄、诊断、肿瘤大小和潜在血管生成以及手术类型的匹配;进行匹配时不了解结果。在单变量和多变量分析中,评估了年龄、肿瘤大小、栓塞的使用、手术类型和风险、栓塞至手术的间隔时间以及去血管化程度与失血量估计值、红细胞输注量、手术时间和栓塞后肾功能之间的相关性。
总体而言,接受栓塞治疗的患者平均失血量较少(0.90 与 1.77 L;p = 0.002),红细胞输注量(2.15 与 3.56 U;p = 0.020)和手术时间(3.13 与 3.91 小时;p < 0.001)。肿瘤较大与失血量估计值(r = 0.451;p = 0.003)、红细胞输注量(r = 0.50;p = 0.002)和手术时间(r = 0.595;p < 0.001)呈正相关。栓塞至手术的时间间隔或去血管化程度均与失血量或输血体积无关。在开放性髓内钉手术中,经导管动脉栓塞术与失血量、输血体积和手术时间减少相关。对于可获得的患者数量,在经皮内固定术中有髓内钉的情况下,栓塞术并未减少红细胞输注量。在术前肾功能正常的接受栓塞治疗的患者中,肌酐水平保持正常。一名术前肾功能异常的患者发生了轻度短暂、可逆的肾功能变化。
本研究表明,术前栓塞术可能会减少失血量,特别是对于大肿瘤和开放性股骨手术。